Feb 12 (Reuters) - Europe’s drugs regulator said on Friday it had started a real-time review of the COVID-19 vaccine developed by German biopharmaceutical firm CureVac.
The European Medicines Agency said the decision by its human medicines committee to start the "rolling review" was based on the vaccine's preliminary results from laboratory studies and early clinical studies in adults. (bit.ly/3ddSKh4) (Reporting by Pushkala Aripaka in Bengaluru; Editing by Vinay Dwivedi)
我们的标准: 汤森路透“信任原则”